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Abstract
Background: Signal transducer and activator of transcription 3 (STAT3) is activated in majority of ovarian tumors
and confers resistance to cisplatin treatment in patients with ovarian cancer. We have reported previously that
diindolylmethane (DIM) inhibits the growth of ovarian cancer cells. However, to date the exact mechanism by
which DIM induces growth suppressive effects has not been clear. In this report the mode of action of DIM is
investigated.
Methods: Six human ovarian cancer cell lines and an ovarian tumor xenograft animal model were used to study
the effect of diindolylmethane alone or in combination with cisplatin.
Results: Diindolylmethane treatment induced apoptosis in all six ovarian cancer cell lines. Phosphorylation of STAT3
at Tyr-705 and Ser-727 was reduced by DIM in a concentration-dependent manner. In addition, diindolylmethane
treatment inhibited nuclear translocation, DNA binding, and transcriptional activity of STAT3. Interleukin (IL)-6-
induced phosphorylation of STAT3 at Tyr-705 was significantly blocked by DIM. Overexpression of STAT3 by gene
transfection blocked DIM-induced apoptosis. In addition, DIM treatment reduced the levels of IL-6 in ovarian cancer
cells and in the tumors. DIM treatment also inhibited cell invasion and angiogenesis by suppressing hypoxia-
inducible factor 1a (HIF-1a) and vascular epithelial growth factor (VEGF). Importantly, diindolylmethane treatment
potentiated the effects of cisplatin in SKOV-3 cells by targeting STAT3. Oral administration of 3 mg diindolylmethane
per day and subsequent administration of cisplatin substantially inhibited in vivo tumor growth. Western blotting
analysis of tumor lysates indicated increased apoptosis and reduced STAT3 activation.
Conclusions: These findings provide a rationale for further clinical investigation of DIM alone or in combination for
chemoprevention and/or chemotherapy of ovarian cancer.
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Background
Ovarian cancer continues to be a major worldwide
gynecological malignancy. Approximately 25,000 new
cases are diagnosed each year in the USA, and 15,000
patients die of this malignancy [1]. Currently, no suffi-
ciently accurate screening tests to diagnose this
malignancy are available. Consequently, it is detected
only in its late stages leading to minimal survival rates
after diagnosis. At stage III, ovarian cancer metastasizes
and spreads to the surrounding organs such as the peri-
toneum and stomach. By stage IV, ovarian cancer
spreads to distant metastatic organs such as the lungs
and liver. Cisplatin is a well established platinum drug
used to treat various cancers, including ovarian cancer
[2,3]. Patients treated with cisplatin often relapse or do
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doses cisplatin exerts side effects such as nephrotoxicity
and ototoxicity in patients [4]. Several reports suggest
that signal transducer and activator of transcription 3
(STAT3) overexpression is positively associated with cis-
platin resistance [5].
The STATs are a novel class of transcription factors
that are positively associated with the growth and survi-
val of cells [6]. STAT3 is a receptor tyrosine kinase that
is activated either by upstream receptor kinases such as
Janus activated kinases (JAKs) or cytokines such as
interleukin (IL)-6 [7]. When IL-6 binds to its receptors,
it activates STAT3 by phosphorylating it at Tyr-705.
Activation of STAT3 at Tyr-705 leads to formation of a
homodimer that translocates to the nucleus, where it
binds to the promoter regions of several genes that
transactivate STAT3-responsive genes such as Mcl-1,
survivin and cyclin D1 [8-10]. It is also phosphorylated
at Ser-727, which is not required for DNA binding
activity but is important for its maximal transcriptional
activity. STAT3 activates vascular endothelial growth
factor (VEGF), thereby promoting neovascularization in
tumors [11]. It also regulates hypoxia-inducible factor
1a (HIF-1a) and vascular epithelial growth factor
(VEGF) during hypoxia, leading to hypoxia-induced
angiogenesis [12,13].
Previously published reports suggest that STAT3 is
overexpressed in various tumors, including ovarian
tumors [10]. A recent clinical study scored 322 patients
for overexpression of phosphorylated (p)-STAT3 and
observed that 303 patients were positive for hyperactiva-
tion of STAT3, accounting for 94% of the study group
[14]. Furthermore, various reports indicate the role of
STAT3 in resistance of ovarian cancer to chemotherapy
[5]. Since STAT3 is involved in various aspects of can-
cer growth ranging from tumor initiation, angiogenesis,
and metastasis, it represents an attractive target for
intervention.
3,3’-Diindolylmethane (DIM), an active metabolite of
indole-3-carbinol, is present in cruciferous vegetables
[15]. Accumulating epidemiological evidence indicates
an inverse relationship between intake of cruciferous
vegetables and the risk of ovarian cancer [16]. Several
studies, including those from our laboratory, have sug-
gested that DIM possesses chemopreventive and thera-
peutic properties [17-19]. Moreover, DIM was shown to
be non-toxic to normal cells [20]. A recently concluded
DIM clinical trial demonstrated that 50% of cervical
cancer patients showed improvement [21]. It is also cur-
rently in clinical trials for prostate cancer [22]. The
effects of DIM were recently discussed in detail by
Banerjee et al. [23]. In our previous study, we showed
that DIM exhibits antiproliferative properties in ovarian
cancer cells by causing G2/M cell cycle arrest [17].
However, the mechanism by which DIM inhibits prolif-
eration of ovarian cancer cells was not clear.
I nt h ep r e s e n ts t u d y ,w ep r o v i d ee v i d e n c et h a tD I M
induces apoptosis in ovarian cancer cells by blocking
the activation of STAT3 and its downstream effector
molecules, while IL-6 treatment or overexpression of
STAT3 significantly protects ovarian cancer cells from
DIM-induced apoptosis. Our results also show that DIM
suppresses angiogenesis and metastasis. In addition,
DIM potentiates the effect of cisplatin in inducing apop-
tosis and inhibiting angiogenesis and metastasis. As a
proof of concept, in vivo efficacy of DIM alone and in
combination with cisplatin also was evaluated.
Methods
Chemicals
BR-DIM was a kind gift from Dr Michael Zeligs (Bio
Response, Boulder, CO, USA). Cisplatin was obtained
from Novaplus (Bedford, OH, USA). Antibodies against
cleaved (Cl)-caspase 3, Cl-poly(ADP-ribose) polymerase
(PARP), p-STAT3 (Tyr-705), STAT3, Mcl-1, and survi-
vin were obtained from Cell Signaling Technology (Dan-
vers, MA, USA). VEGF antibody was obtained from
R&D systems (Minneapolis, MN, USA), Lamin B was
from Santa Cruz Biotechnologies (Santa Cruz, CA,
USA), and p-STAT3 (Ser-727) and HIF-1a were
obtained from Abcam Inc. (Cambridge, MA, USA).
Actin antibody, IL-6, MCDB105 and Medium 199 were
procured from Sigma Aldrich (St Louis, MO, USA).
RPMI and McCoy 5A were purchased from Mediatech
(Manassas, VA, USA). NE-PER nuclear fractionation kit
was from Thermo Scientific. EZ-TFA transcription fac-
tor assay kit was obtained from Upstate (Millipore, Bill-
erica, MA, USA). Dual luciferase kit was bought from
Promega (Madison, WI, USA). The VEGF Elisa kit was
from Invitrogen (Carlsbad, CA, USA) and FuGENE 6
was obtained from Roche (South San Francisco, CA,
USA). IL-6 secretion ELISA kit was from ebiosciences
(San Diego, CA, USA).
Cell cultures
SKOV-3, OVCAR-3 and TOV-21G cells lines were pro-
cured from American Type Culture Collection (ATCC;
Manassas, VA, USA). SKOV-3 cells were maintained in
McCoy’s 5A medium supplemented with 10% fetal
bovine serum (FBS). OVCAR-3 cells were maintained in
RPMI medium supplemented with 20% FBS, 10 mM
sodium pyruvate, 10 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES), 10 mg/l bovine insulin
and 4.5 g/l glucose. Human normal ovarian surface
epithelium cells (NOSE) were a kind gift from Dr Jin-
song Liu at MD Anderson, Houston, TX, USA. NOSE
cells were previously transfected with the SV40 early
region expressing large T and small t antigens as
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maintained in 1:1 mixture of MCDB105 and Medium
199 supplemented with 15% FBS. The A2780 cell line (a
kind gift from Dr Thomas Hamilton, Fox Chase Cancer
Center, Philadelphia, PA, USA) was maintained in RPMI
media supplemented with 10% FBS and 2.7 units/ml
insulin. OVCAR-429 and OVCAR-433 (a kind gift from
Dr Laurie Hudson, University of New Mexico) were
maintained in Dulbecco’s modified Eagle medium
(DMEM) with 10% FBS. A 1% antibiotic mixture was
used in all the above media. All the cell lines were
maintained at 37°C in a humidified incubator circulated
with 5% CO2/95% air. The cell survival assay was per-
formed as described by our group previously [17].
Annexin V apoptosis assay
SKOV-3 cells were plated at a density of 0.3 × 10
6 cells
per well in a six-well plate and allowed to attach over-
night. Cells were then treated with or without DIM.
After 24 h cells were exposed to IL-6 for 15 minutes,
washed, suspended in binding buffer, and incubated for
15 minutes with annexin V-FITC (BD Biosciences, San
Jose, CA, USA). Fluorescence was measured using a C6
Accuri flow cytometer (Ann Arbor, MI, USA) with a
minimum of 10,000 events per sample as previously
described by our group [25].
Western blot analysis
SKOV-3, OVCAR-3, TOV-21G and A2780 cells were
exposed to varying concentrations of DIM alone or in
combination with cisplatin. Cells were collected, lysed,
and about 20 to 80 μg protein was subjected to SDS gel
electrophoresis followed by immunoblotting as pre-
viously described by our group [26].
Nuclear fractionation
SKOV-3, OVCAR-3, TOV-21G, or A2780 cells were
plated at a density of 1 × 10
6 in 100 mm culture dishes
and exposed to different concentrations of DIM for 24
h. Nuclear fraction was extracted using NE-PER kit
from Thermo Scientific according to the manufacturer’s
instructions.
STAT3 DNA binding activity
DNA binding activity of STAT3 was measured by Uni-
versal EZ-TFA transcription factor assay colorimetric
kit. SKOV-3 or OVCAR-3 cells were treated with or
without DIM for 24 h. Nuclear extracts were used to
determine the specific STAT3 DNA binding activity as
previously described by our group [27].
STAT3 luciferase reporter assay
Transcriptional activity of STAT3 was determined in
SKOV-3 and OVCAR-3 cells by transfecting the cells with
2 μg pLuc-TK/STAT3, which encoded firefly luciferase
under the control of STAT3 promoter, and with 0.2 μgo f
a pRL-TK, which constitutively expressed Renilla lucifer-
ase, the latter as a transfection efficiency control. At 24 h
after transfection, cells were treated with or without DIM
for 24 h. Whole cell lysates were collected using passive
lysis buffer provided by dual luciferase reporter assay kit.
Renilla and firefly luciferase activities were measured by a
luminometer. Firefly luciferase activities were corrected for
Renilla values and then normalized relative to dimethyl-
sulfoxide (DMSO) control as previously described [27].
IL-6 treatment
SKOV-3, OVCAR-3, or TOV-21G cells were treated with
75 μM DIM for 24 h followed by incubation with 10 ng/
ml IL-6 for 15 minutes. Cells were then processed for
apoptosis assay or western blotting as described above.
MG132 treatment
Since HIF-1a is proteasomally degraded, SKOV-3 and
OVCAR-3 cells were pretreated with 10 μMM G 1 3 2f o r
1 h and then treated with 75 μM DIM for 6 h. In another
experiment, after DIM treatment, cells were treated with
or without 10 ng/ml IL-6 for 15 minutes. Samples were
processed for western blotting as described above.
STAT3a overexpression
A total of 0.3 × 10
6 SKOV-3 cells were plated in
McCoy’s 5A medium containing 10% FBS without anti-
biotics and allowed to attach overnight. Complexes were
prepared by incubating 2 μg STAT3a plasmid with 6 μl
FuGENE 6 transfection reagent in 100 μl McCoy media
without serum or antibiotic for 1 h. These complexes
were then added to the cells. At 6 h after transfection,
the media was replaced by regular media. After 24 h of
transfection, cells were further treated with or without
DIM for 24 h.
STAT3 small hairpin (sh)RNA
A total of 0.3 × 10
6 SKOV-3 cells were plated in
McCoy’s 5A medium containing 10% FBS without anti-
biotics and allowed to attach overnight. Complexes were
prepared by incubating 2 μg STAT3 shRNA with 6 μl
FuGENE 6 transfection reagent in 100 μl McCoy media
without serum or antibiotic for 1 h. These complexes
were then added to the cells. At 6 h after transfection,
media was replaced by regular media. After 24 h of
transfection, cells were processed for apoptosis assay as
described above.
Estimation of IL-6 secretion by ELISA
About 10,000 SKOV-3, OVCAR-3 or OVCAR-429 cells
were plated per well in a 96-well plate. Cells were
starved overnight followed by treatment with DIM for
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for measuring secreted IL-6 levels using ELISA kit
according to manufacturer’s instructions.
Aortic ring assay
Aortic ring spouting assay was performed as previously
described [28]. In brief, 1 mm long rings were excised
from rat thoracic aorta. The rings were submerged in
350 μL Matrigel (BD Biosciences) containing 50 ng/ml
IL-6. After a 24-h incubation, DIM, cisplatin, or both
were added to the rings and incubated for an additional
3 to 5 days. The aortic rings that formed microvascular-
like sprouts were photographed under light microscope
(Olympus Inc., PA, USA) and the results were quantified
by ImageJ V.1.43 software provided by NIH.
Estimation of VEGF secretion by ELISA
Secreted VEGF levels in DIM treated SKOV-3 and
OVCAR-3 cell culture medium were measured using
ELISA kit according to manufacturer’s instructions.
Wound healing assay
Wound healing assay was performed as described pre-
viously [29]. Confluent monolayers of SKOV-3;
OVCAR-3; and TOV-21G cells in six well plates were
scratched with a 1 ml pipette tip and incubated in
respective medium containing 50 μM DIM. Cells were
photographed under a light microscope (Olympus) at 0,
24 and 48 h and the results were quantified by ImageJ
software (NIH).
Transwell cell invasion assay
Cell invasion was performed according to the manufac-
turer’s instructions in transwell Boyden’sc h a m b e r sw i t h
8.0 μm pore size filters (BD Biosciences). Briefly, cells
were serum starved overnight and harvested by trypsini-
zation. A suspension of 20,000 SKOV-3 cells in 600 μL
McCoy medium containing 1% serum were seeded on
the upper well of the Boyden’s chamber and the lower
chamber was filled with 1.5 ml of media containing 1%
serum. After incubation for 2 h, DIM or cisplatin or
both were added to the upper chamber whereas 10%
FBS and 20 ng/ml VEGF was added to the lower cham-
ber as chemoattractant. After incubation for 24 h, cells
from the upper chamber were removed by wiping with
a cotton swab, and the filter was fixed with 10% tri-
chloroacetic acid (TCA) and stained with 0.4% (w/v) sul-
forhodamine B (SRB) solution. The filters containing
stained cells were removed from the transwell chambers
and individually transferred to individual wells in a 96-
well plate. The SRB dye retained on the filter was
extracted with 10 mM Tris buffer and the absorbance
was measured at 570 nm using a microplate reader (Bio-
Tek Instruments, VT, USA). Assays were performed in
duplicates and data was expressed as percent migration
with control.
In vivo xenograft experiment
Female athymic nude mice, 4 to 6 weeks old, were pur-
chased from Charles River Laboratories (Wilmington,
MA, USA). The use of mice and their treatment was
approved by Institutional Animal Care and Use Com-
mittee (IACUC), Texas Tech University Health Sciences
Center, and all the experiments were carried out in
strict compliance with regulations. Mice were fed with
antioxidant-free AIN-76A special diet for a week before
starting the experiment. About 5 × 10
6 SKOV-3 cells
were injected subcutaneously into both right and left
flanks. Eight mice were assigned randomly to each
group. Since each mouse was implanted two xenografts,
each group had 16 tumors. Once each mouse achieved a
tumor of about 90 mm
3, the control group received PBS
whereas mice in the treatment group received 3 mg
DIM suspended in PBS by oral gavage every day. At day
34, 5 mg/kg cisplatin was injected intraperitoneally to
the treatment group mice. Beginning on the 7th day
after cell implantation, tumor volume was measured
three times a week using vernier calipers until day 48,
as previously described by our group [27]. On day 48
the mice were killed and tumors were removed for wes-
tern blot analysis.
SRB cell survival assay
Around 5,000 cells in 0.1 ml medium were plated per
well in 96 well plates and allowed to attach overnight.
Desired concentrations of DIM were added to the cells
and incubated at 37°C for 24 h. The cells were then pro-
cessed and stained with 0.4% SRB solution and the
absorbance was read at 570 nm using a Biotek plate
reader as described by our group previously [17].
Statistical analysis
All the statistical analyses were performed using Prism
5.0 (GraphPad Software Inc., San Diego, CA, USA). The
data represents mean values with SD. The Student’st
test was used to compare the control and treated
groups. In experiments involving more than three
groups, non-parametric analysis of variance followed by
Bonferroni post hoc multiple comparison test was used.
All statistical tests were two sided. Differences were
considered statistically significant when the P value was
less than 0.05.
Results
DIM induces apoptosis in ovarian cancer cells
We previously reported that DIM inhibits the growth of
ovarian cancer cells by causing cell cycle arrest [17];
however, the exact mechanism was not clear. The
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ovarian cancer cells using annexin V-FITC. Treatment
of SKOV-3 cells with 50 μMo r7 5μMD I Mf o r2 4h
resulted in an approximately 2.8-fold to 5.2-fold increase
in apoptosis (Figure 1A). To rule out the cell specific
effects of DIM, we evaluated DIM-induced apoptosis in
five other ovarian cancer cell lines. Our results showed
that apoptosis induced by DIM was nearly 3.6-fold to
5.2-fold higher in OVCAR-3, 4.9-fold to 7.1-fold higher
in TOV-21G, 10.1-fold to 11.8-fold higher in A2780,
fourfold to fivefold higher in OVCAR-429 and threefold
to fourfold higher in OVCAR-433 cells (Figure 1A).
Apoptosis-inducing effects of DIM were further con-
firmed by western blot analysis that revealed the clea-
vage of caspase 3 and PARP in DIM-treated ovarian
cancer cells (Figure 1B). These results clearly establish
that DIM induces apoptosis in ovarian cancer cells.
DIM targets the STAT3 pathway
Our next step was to investigate the mechanism by which
DIM induces apoptosis. STAT3 is activated in almost
90% of ovarian cancers. Overexpression of STAT3 was
reported in stage III and IV ovarian tumors [14]. We
hypothesized that DIM induces apoptosis in ovarian can-
cer cells by inhibiting STAT3, and then systematically
tested our hypothesis. SKOV-3, OVCAR-3, TOV-21G,
A2780, OVCAR-429 and OVCAR-433 cells treated with
varying concentrations of DIM were subjected to western
blotting. Our results clearly show that DIM substantially
inhibits the activation of STAT3 by suppressing phos-
phorylation at Tyr-705 and Ser-727 (Figure 2A i-vi). The
protein levels of STAT3 decreased modestly with DIM
treatment. Our results further show that the expression
of Mcl-1 and survivin were drastically decreased by DIM
treatment in a concentration-dependent manner in all
four cell lines (Figure 2A i-iv). Regulated by STAT3, both
Mcl-1 and survivin have been implicated in cancer
growth. These results demonstrate that DIM targets
STAT3 pathway in ovarian cancer cells.
DIM inhibits nuclear translocation of STAT3
Once phosphorylated at Tyr-705, STAT3 forms a homo-
dimer and translocates into the nucleus where it gets
involved in the transcription of cell survival genes such
as Mcl-1, survivin. Our results show that nuclear trans-
location of STAT3 was blocked by DIM treatment in
SKOV-3, OVCAR-3, TOV-21G and A2780 cells (Figure
2B i-iv) and strengthen our hypothesis that DIM inhibits
the growth of ovarian cancer cells by blocking STAT3.
DIM inhibits DNA binding activity and transcriptional
activity of STAT3
Upon translocating to the nucleus, STAT3 binds to spe-
cific response elements in the promoter regions of its
responsive genes. Since we observed that DIM blocked
the nuclear translocation of STAT3, our next step was
to determine whether DIM can inhibit DNA binding
and transcriptional activity of STAT3. DNA-binding
activity of STAT3 was determined by Universal EZ-TFA
transcription factor colorimetric assay using the nuclear
lysates of cells treated with or without DIM. Our results
show that DIM treatment resulted in approximately 60%
inhibition of DNA binding activity in SKOV-3 cells (Fig-
ure 2C i). Around 30% inhibition of DNA binding activ-
ity was observed in OVCAR-3 cells by DIM (Figure 2C
ii).
We then evaluated the transcriptional activity of
STAT3 by luciferase assay. We observed a dramatic
reduction in STAT3 transcriptional activity by DIM
treatment. In SKOV-3 and OVCAR-3 cells, transcrip-
tional activity was reduced by 80% (Figure 2D i, ii).
Similarly, in TOV21G and A2780 cells, transcriptional
activity decreased by 90% (Figure 2D iii, iv).
DIM inhibits IL-6-induced activation of STAT3
STAT3 can be activated by IL-6, a cytokine that binds
to its receptor and phosphorylates at Tyr-705. Exposing
SKOV-3 or OVCAR-3 cells to 10 ng/ml IL-6 for 15
minutes led to an enormous activation of STAT3 (Fig-
ure 3A,B). However, IL-6 treatment failed to induce a
significant activation of STAT3 in DIM treated cells
(Figure 3A i, B i, C). STAT3 protein level was not
affected by IL-6 treatment (Figure 3A i). We further
observed that IL-6 treatment significantly blocked DIM-
induced cleavage of caspase 3 and PARP (Figure 3A).
These results were confirmed by annexin staining show-
ing that IL-6 significantly blocked DIM-induced apopto-
sis (Figure 3A ii). Similarly, in OVCAR-3 cells, apoptosis
induced by DIM was significantly blocked by IL-6 (Fig-
ure 3B ii).
Ectopic expression of STAT3 abrogates DIM-induced
apoptosis
To further strengthen our observation that DIM-
induced apoptosis was mediated by STAT3 inhibition in
ovarian cancer cells, we transiently transfected SKOV-3
cells with STAT3 encoding plasmid for 24 h, resulting
in an almost twofold increase in the expression of
STAT3 (Figure 3E i). Correspondingly, phosphorylation
of STAT3 at both Tyr-705 and Ser-727 also increased
substantially. STAT3 overexpression completely pro-
tected SKOV-3 cells from DIM-induced apoptosis as
evaluated by cleavage of caspase 3 and PARP (Figure 3E
i). These observations were further confirmed by
annexin V apoptosis assay by flow cytometry (Figure 3E
ii). Taken together, our results clearly indicate that
apoptosis induced by DIM was almost completely
blocked in the cells overexpressing STAT3 (Figure 3D
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Figure 1 Diindolylmethane (DIM) induces apoptosis in ovarian cancer cells. (A) SKOV-3, OVCAR-3, TOV-21G, A2780, OVCAR-429 and OVCAR-
433 cells were treated with or without 50 μMo r7 5μM DIM for 24 h. Cells that were positive for annexin or propidium iodide (PI) or both were
measured using flow cytometry. Representative images are shown. (B) Representative western blots of cleaved caspase 3 and cleaved poly(ADP-
ribose) polymerase (PARP) from the lysates collected from (i) SKOV-3, (ii) OVCAR-3, (iii) TOV-21G, (iv) A2780, (v) OVCAR-429 and (vi) OVCAR-433
cells treated with or without 75 μM DIM.
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Figure 2 Diindolylmethane (DIM) inhibits signal transducer and activator of transcription 3 (STAT3) pathway in ovarian cancer cells.
(A) Representative blots showing the concentration-dependent effect of DIM on phosphorylated (p)-STAT3 (Tyr-705), p-STAT3 (Ser-727), STAT3,
Mcl-1, survivin in (i) SKOV-3, (ii) OVCAR-3, (iii) TOV-21G and (iv) A2780 ovarian cancer cells. Concentration-dependent effect of DIM on p-STAT3
(Tyr-705) and STAT3 in (v) OVCAR-429 and (vi) OVCAR-433 cells. Actin was used as loading control. (B) Effect of DIM on nuclear translocation of
p-STAT3 and STAT3. Representative blots of nuclear lysates of (i) SKOV-3, (ii) OVCAR-3, (iii) TOV21G and (iv) A2780 cells treated with DIM. Lamin
B was used as loading control. (C) Effect of DIM on STAT3 DNA binding. (i) SKOV-3 cells or (ii) OVCAR-3 cells were treated for 24 h with or
without 75 μM DIM and nuclear cell extracts were tested for STAT3 DNA-binding activity as measured by the Universal EZ-TFA transcription
factor colorimetric assay. (D) Effect of DIM on STAT3-regulated luciferase reporter activity. STAT3 luciferase transcriptional activity was determined
in (i) SKOV-3, (ii) OVCAR-3, (iii) TOV21G or (iv) A2780 cells. Firefly luciferase activities were corrected for Renilla luciferase levels and then
normalized relative to the control, which was considered as 100%. Means and SD of two independent experiments performed in triplicate are
shown. The Student’s t test was used for statistical analysis to compare control and DIM treatment.
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Figure 3 Diindolylmethane (DIM) suppresses signal transducer and activator of transcription 3 (STAT3) activated by interleukin (IL)-6
or in cells overexpressing STAT3. Effect of DIM on STAT3 activation and apoptosis. (A) (i) SKOV-3, (B) (i) OVCAR-3 or (C) (i) TOV-21G cells
were stimulated with 10 ng/ml IL-6 for 15 minutes after treatment with 75 μM DIM for 24 h. Whole cell lysates were resolved on 10% SDS-PAGE
for the analysis of STAT3 phosphorylation at Tyr-705 and Ser-727, STAT3 expression, and cleavage of caspase 3 and poly(ADP-ribose) polymerase
(PARP). Actin was used as a control for loading. Effect of IL-6 on apoptosis was also determined in (A) (ii) SKOV-3 and (B) (ii) OVCAR-3 cells. (D)
Effect of STAT3 small hairpin (sh)RNA on apoptosis was also determined in SKOV-3 cells. (E) Effect of DIM on STAT3 activation, STAT3 expression,
and apoptosis in SKOV-3 cells overexpressing STAT3. Cells were transfected with an empty vector or a plasmid expressing STAT3 for 24 h and
treated with 75 μM DIM for another 24 h. (E) (i) Whole cell lysates were analyzed by western blotting. (E) (ii) Effect of STAT3 overexpression on
DIM-induced apoptosis was determined by flow cytometry. (F) Effect of DIM on IL-6 secretion was determined in (F) (i) SKOV-3, (ii) OVCAR-3 and
(iii) OVCAR 429 cells. The experiments were repeated three times and similar results were obtained. The differences between all the groups were
compared by non-parametric analysis of variance with Bonferroni post hoc comparisons.
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cancer cells.
Silencing STAT3 using shRNA induces apoptosis in SKOV-
3 cells
To address whether or not inhibition of STAT3 induces
apoptosis in ovarian cancer cells, we silenced STAT3
using shRNA in SKOV-3 cells. Supporting our hypoth-
esis, our results show that silencing STAT3 resulted in
about 35% apoptosis in SKOV-3 cells suggesting the cri-
tical role of STAT3 in ovarian cancer cells (Figure 3D).
Our results are in agreement with a previously pub-
lished study that showed that STAT3 specific inhibitor
(AG490) induced apoptosis in ovarian cancer cells [30].
DIM inhibits IL-6 secretion
IL-6, a cytokine, activates STAT3 by phosphorylating it
at Tyr-705. High levels of circulating IL-6 were observed
in ovarian cancer patients [31]. Since we observed that
DIM can suppress IL-6-induced activation of STAT3 in
ovarian cancer cells, we hypothesized that DIM
mediated inhibition of STAT3 is in fact by inhibition of
IL-6. We therefore measured IL-6 secretion by ovarian
cancer cells using a commercial ELISA kit. Our results
demonstrate that DIM drastically blocks the secretion of
IL-6 in SKOV-3, OVCAR-3 and OVCAR-429 cells (Fig-
ure 3F i-iii). Reduction in IL-6 secretion levels ranged
from 60% to 80% in three different cell lines.
DIM inhibits cell migration and neovascularization
Recent literature suggested a novel role of STAT3 in
angiogenesis and metastasis. Since DIM suppressed the
activation of STAT3 in ovarian cancer cells, we wanted
to test whether DIM can inhibit invasion and angiogen-
esis. We first determined the anti-invasive potential of
DIM by evaluating cell migration in a wound healing
assay. A wound was made on confluent monolayer cells
with a pipette tip and, after washing with fresh medium,
cells were treated with or without 50 μMD I M .O u r
results revealed that after 24 h DIM treatment, SKOV-3
cells migrated into 20% of the wounded area, whereas
control cells migrated into 80% of the wounded area,
showing the potential anti-invasive property of DIM
(Figure 4A). Similar observations were made in
OVCAR-3 and TOV-21G cells (Figure 4B, C).
Since several studies have established the role of acti-
vated STAT3 in tumor angiogenesis, we next sought to
determine the antiangiogenic potential of DIM. We used
an aortic ring model where microvessel sprouting occurs
in response to growth stimulatory signals. Treatment
with IL-6 induced a massive microvessel formation on
rat aortic rings after 24 h of incubation. However,
microvessel sprouting was drastically reduced in aortic
rings treated with DIM (Figure 4D).
STAT3 positively regulates HIF-1a and VEGF under
hypoxia. VEGF has also been shown to be regulated by
STAT3 in an HIF-1a-dependent manner [13]. Under nor-
mal conditions, HIF-1a is constitutively synthesized and
subjected to proteasomal degradation to maintain minimal
levels. In order to determine the effect of DIM on HIF-1a
expression, cells were treated with MG132, a known pro-
teasomal inhibitor, in the presence or absence of DIM.
Our results show that HIF-1a expression was drastically
increased after 6 h of MG132 treatment. However, treat-
ment of SKOV-3 or OVCAR-3 cells with DIM after
MG132 treatment did not result in the accumulation of
HIF-1a (Figure 4E). These results indicate that DIM sup-
presses HIF-1a induction (Figure 4E). To delineate the
role of STAT3 in DIM-mediated HIF-1a down regulation,
cells were treated with IL-6, which activates STAT3 phos-
phorylation, leading to the induction of HIF-1a.O u r
results further show that IL-6-induced HIF-1a expression
was significantly attenuated by DIM (Figure 4F). VEGF
expression, which normally is regulated by HIF-1a,w a s
also substantially reduced by DIM treatment (Figure 4F).
These results provide critical evidence that DIM inhibits
angiogenesis in ovarian cancer cells by downregulating
HIF-1a and VEGF through STAT3.
DIM potentiates the effect of cisplatin
We wanted to determine whether DIM can potentiate
the effect of cisplatin, a drug used to treat ovarian can-
cer patients. Cisplatin usually is associated with several
side effects such as renal toxicity and reduction of white
and red blood cells. Moreover, tumors often become
resistant to cisplatin therapy. Hence, enhancing the
effect of cisplatin at low doses by agents that are non-
toxic may be a better strategy, not only for effective
treatment but also to reduce harmful side effects. To
test whether or not DIM potentiates the effect of cispla-
tin, SKOV-3 cells were treated with 20 μMo r5 0μM
DIM for 24 h followed by exposure to 10 μMc i s p l a t i n
for an additional 24 h. It is important to mention that
the IC50 of cisplatin in SKOV-3 cells is 40 μM; we used
one-quarter of the IC50 concentration. Growth inhibi-
tion in combination treatment was significantly higher
as compared to either treatment alone (Figure 5A). We
observed around 50% to 70% reduction in the survival
of SKOV-3 cells treated with a combination of DIM and
cisplatin as compared to 28% by cisplatin alone (P <
0.001). We calculated the combination index (CI) for
DIM and cisplatin combination treatment in SKOV-3
cells. CI values for the combination of cisplatin with 20
μMa n d5 0μM DIM treatment were 0.45 and 0.56,
respectively, indicating the synergistic effect of DIM
with cisplatin.
We next wanted to identify the mechanism behind the
synergistic effects of DIM with cisplatin. We
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Figure 4 Diindolylmethane (DIM) blocks cell migration and neovascularization by inhibiting hypoxia-inducible factor 1a (HIF-1a) and
vascular epithelial growth factor (VEGF). (A) SKOV-3, (B) OVCAR-3 or (C) TOV21G cells were plated, scratched with a pipette tip and
incubated in the absence or presence of 50 μM DIM. Photographs were taken at 0 h and 24 h using an inverted microscope. The wound area in
DIM treated and control cells were quantified by ImageJ software. Results are presented as means ± SD of triplicates. (D) DIM inhibits interleukin
(IL)-6-induced vessel sprouting ex vivo. Representative photographs are presented. (E) Effect of DIM on proangiogenic proteins was analyzed by
western blotting. SKOV-3 or OVCAR-3 cells were treated with 10 μM MG132 for 1 h and then exposed to 75 μM DIM for 6 h. (F) Cells were
treated as above and then treated with IL-6 for 15 minutes. Representative blots of HIF-1a and VEGF are shown. Blots were further stripped and
probed with actin. Experiments were performed independently three times. The Student’s t test was used for statistical analysis to compare
control and DIM treatment.
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Figure 5 Diindolylmethane (DIM) potentiates the effect of cisplatin in ovarian cancer cells. (A) SKOV-3 cells were exposed to 20 or 50 μM
DIM for 24 h, followed by exposure to 10 μM cisplatin for another 24 h. Survival of control and treated cells was evaluated by sulforhodamine B
assay. (B) Combination effect of cisplatin and DIM on the signal transducer and activator of transcription 3 (STAT3) pathway. Representative blots
of control and treated cells were examined for Tyr-705 and Ser-727 STAT3, STAT3, Mcl-1, survivin, cleaved poly(ADP-ribose) polymerase (PARP),
and cleaved caspase 3. Blots were stripped and probed with actin. (C) Effect of combination treatment on nuclear localization of STAT3. Nuclear
fractions from cells treated with or without 50 μM DIM or 10 μM cisplatin or both were subjected to western blotting. Representative blots of
Tyr-705 STAT3 and STAT3 are shown. Lamin B was used as loading control. (D) Luciferase activity in combination treatment was measured in
SKOV-3. Whole cell lysates were collected and firefly luciferase activities were corrected for Renilla luciferase levels and then normalized relative
to the control, which was considered as 100%. (E) Aortic rings (1 mm) were harvested from Sprague-Dawley rats, immersed in matrigel, and
treated with interleukin (IL)-6 (50 ng/ml) in the absence or presence of cisplatin (10 μM) with or without DIM (50 μM) for 4 days, and then
photographed under a microscope (4 ×). Representative photographs are shown. (F) DIM inhibits the invasion of SKOV-3 cells. Invasion assay
was performed using Boyden’s chamber (BD Sciences) according to manufacturer’s instructions. (G) DIM inhibits vascular epithelial growth factor
(VEGF) secretion. Cells were plated, stimulated with VEGF, and treated with DIM for 24 h. Media was collected and assayed for VEGF by ELISA
(Invitrogen) kit according to manufacturer’s instructions. All experiments were performed independently three times. The differences between all
the groups were compared by non-parametric analysis of variance with Bonferroni post hoc comparisons.
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DIM was due to modulation of STAT3 pathway. In agree-
ment with our hypothesis, combination treatment strongly
suppressed the activation of STAT3 at Tyr-705 or Ser-727
as compared to cisplatin only treatment (Figure 5B). Mcl-
1 also was downregulated in a similar manner. It is impor-
tant to note that survivin, which is a positive regulator of
growth and a major downstream target of STAT3, was
drastically upregulated by cisplatin treatment alone. None-
theless, DIM completely blocked cisplatin-mediated upre-
gulation of survivin in the combination treatment (Figure
5B). Increased cleavage of caspase 3 and PARP by combi-
nation treatment indicated significantly more apoptosis as
compared to either treatment alone. Furthermore, combi-
nation treatment completely abolished the phosphoryla-
tion and reduced the expression of STAT3 in the nuclear
fraction of cells (Figure 5C). Similarly, transcriptional
activity of STAT3 was also significantly suppressed by
combination treatment (Figure 5D).
We then wanted to know if combination treatment
could inhibit angiogenesis in a rat aorta model. Our
data showed that after 72 h, microvessel sprouting in rat
aorta was not suppressed by cisplatin treatment (Figure
5E). However, combination treatment completely
blocked microvessel sprouting (Figure 5E). The combi-
nation treatment of DIM with cisplatin also significantly
blocked the invasion of the cells as evaluated by the
Boyden’s chamber technique (Figure 5F). However, cis-
platin alone had hardly any inhibitory effect on the inva-
sion of cells (Figure 5F). We also tested whether DIM
alone or in combination inhibited VEGF secretion. Our
results clearly demonstrate that DIM treatment in com-
bination with cisplatin decreased the VEGF secretion by
60% as compared to control or cisplatin treatment only
in both SKOV-3 and OVCAR-3 cells (Figure 5G).
DIM treatment alone and with cisplatin inhibits ovarian
tumor growth
We demonstrated that DIM induces apoptosis in ovar-
ian cancer cells and enhances the effect of cisplatin by
inhibiting STAT3 pathway in culture models. To vali-
date these effects in vivo, we performed a tumor xeno-
graft assay. About 5 × 10
6 SKOV-3 cells were injected
subcutaneously into both the right and left flanks of
female athymic nude mice. Once each mouse had a
tumor of about 90 mm
3,t h e yw e r er a n d o m i z e di n t o
four groups. DIM treatment started 24 days after tumor
implantation, and cisplatin treatment began 10 days
later. Our results demonstrated that DIM alone and in
combination treatment substantially retarded the growth
of SKOV-3 tumors as compared to control or cisplatin
treatment. For example, at day 48 the average tumor
volume in control mice and cisplatin-treated mice was
around 400 mm
3 and 300 mm
3, respectively, whereas
t h ea v e r a g et u m o rv o l u m ei nm i c et h a tr e c e i v e dD I M
alone or in combination with cisplatin was 210 mm
3
and 138 mm
3, respectively (Figure 6A). The combina-
tion treatment suppressed tumors by 65% as compared
to controls. Interestingly, there was no significant
change in the weight of mice treated with DIM as com-
pared to mice in the control group. The weight of mice
declined significantly in response to cisplatin treatment.
However, the decline in weight in the combination
treatment group was not as significant as in the mice
receiving cisplatin treatment alone (Figure 6A ii). To
determine whether DIM-mediated tumor growth sup-
pression was due to inhibition of STAT3, tumor lysates
were subjected to western blotting. As shown in Figure
6B, p-STAT3 (Tyr-705), STAT3, and Mcl-1 were down-
regulated in the tumors of mice treated with DIM alone
or in combination with cisplatin as compared to control
or cisplatin treatment. Furthermore, cleavage of caspase
3 and PARP increased significantly in the tumors of
mice treated with combination, yet again confirming
that DIM suppressed tumor growth by inducing apopto-
sis in vivo.F u r t h e r m o r e ,I L - 6l e v e l si nt u m o rl y s a t e s
from DIM treated mice were significantly less as com-
pared to levels in the tumor lysates from control mice
(Figure 6D). Taken together, our results clearly establish
that DIM induces apoptosis in ovarian cancer cells in
vitro and in vivo by targeting the STAT3 pathway and
synergistically enhancing the effects of cisplatin.
DIM is minimally toxic to normal human ovarian surface
epithelial cells
In order to determine whether DIM is toxic to normal
ovarian cells, we treated NOSE cells with various con-
centrations of DIM for 24 h. Interestingly, our results
showed that DIM treatment caused minimal reduction
in the survival of non-tumorigenic ovarian cells (Figure
7A). At a concentration as high as 120 μM, DIM
reduced the survival of NOSE cells by about 25%,
whereas a 75% reduction in survival was observed in
TOV-21G ovarian cancer cells (Figure 7A). These
results indicate that DIM is minimally toxic to normal
ovarian surface epithelial cells.
To gain further insight into the effect of DIM on p-
STAT3, NOSE cells were treated with varying concen-
trations of DIM for 24 h. Surprisingly, we observed
phosphorylation of STAT3 in these cells and 75 μM
DIM significantly reduced STAT3 phosphorylation (Fig-
ure 7B). Although STAT3 is mainly known to be acti-
vated and/or overexpressed in tumorigenic cells, a few
recent studies have suggested that IL-6 and STAT3 are
activated at low levels in normal ovaries [14,32]. How-
ever, the exact mechanism and role of activated STAT3
in normal ovaries is not clear. Our results clearly show
that STAT3 is a target of DIM.
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Figure 6 Diindolylmethane (DIM) suppresses the growth of ovarian tumors alone and in combination with cisplatin by inhibiting
signal transducer and activator of transcription 3 (STAT3) in nude mice. SKOV-3 tumor cells were implanted into athymic nude mice. Once
each mouse had a palpable tumor, mice received 3 mg/day DIM by oral gavage every day or 5 mg/kg cisplatin intraperitoneally twice a week or
both. (A) (i) Effect of DIM on tumor growth. *P < 0.05 when compared to control. (ii) Tumor weight of mice from different groups during the
course of in vivo study. (B) Inhibition of STAT3 signaling in the tumors of mice administered with DIM alone or in combination with cisplatin.
Tumors from control and treated mice were excised on day 48 after implantation, lysed and analyzed by western blotting for Tyr-705 STAT3, Ser-
727 STAT3, total STAT3, Mcl-1, survivin, cleaved poly(ADP-ribose) polymerase (PARP) and cleaved caspase 3. Blots were stripped and reprobed
with actin antibody to verify equal protein loading. Each lane represents a different tumor sample. (C) Densitometric quantitation of western
blotting represented above. Legends on the bars indicate (a) statistically significant compared to control, (b) statistically significant compared to
DIM, (c) statistically significant compared to cisplatin. (D) Levels of interleukin (IL)-6 in tumors from control mice and DIM treated mice. The
differences between all the groups were compared by non-parametric analysis of variance with Bonferroni post hoc comparisons.
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Our results demonstrate that DIM suppresses the
growth of ovarian cancer cells and potentiates the effect
of cisplatin in vitro and in vivo by targeting STAT3 sig-
naling without being toxic to normal ovarian cells. To
the best of our knowledge, this is the first report
demonstrating STAT3 as a target of DIM. Accumulated
evidence indicates the involvement of STAT3 in the
transformation of normal cells into malignant ones
[30,33]. STAT3 is overexpressed in ovarian tumors and
is associated with ovarian tumorigenesis [14]. A recent
study demonstrated that STAT3 is activated in 94% of
ovarian cancer patients [14]. Furthermore, STAT3 is
also implicated in resistance to chemotherapy in ovarian
cancer [5]. Our studies showed that DIM-induced apop-
tosis in various ovarian cancer cells was mediated by
substantially suppressing the phosphorylation of STAT3
at Tyr-705 and Ser-727. Tyrosine phosphorylation is
mainly associated with oncogenic status of STAT3. The
effects of DIM were not specific to only SKOV-3 cells
p-STAT3 (Tyr 705)
STAT3
Actin
0              25        50         75
DIM Concentration (μM)
NOSE
24 hours
A
B
Figure 7 Diindolylmethane (DIM) is minimally toxic to normal ovarian surface epithelium cells. (A) Effect of varying concentrations of
DIM in NOSE and TOV-21G cells was determined by sulforhodamine B cell survival assay. Values are means ± SD of two independent
experiments with eight replicates. (B) In another experiment, NOSE cells were exposed to different concentrations of DIM for 24 h. Cells were
lysed and western blotting was performed as outlined in Methods. Representative immunoblots show the effect of DIM on the expression of
phosphorylated signal transducer and activator of transcription 3 (p-STAT3) (Tyr 705) and STAT3. Blots were stripped and probed with actin to
ensure proper loading.
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ian cancer cell lines such as OVCAR-3, TOV-21G,
A2780, OVCAR-429 and OVCAR-433. These studies
agree with previous reports that demonstrate that inhi-
biting constitutive activation of STAT3 by STAT3 inhi-
bitor AG490 inhibits tumor growth [34].
Unphosphorylated STAT3 resides in the cytoplasm
and is activated by phosphorylation. Once phosphory-
lated at Tyr-705, STAT3 dimerizes and translocates into
the nucleus [35,36]. Around 86% of ovarian tumor tis-
sues have activated STAT3 in the nucleus and not in
the cytoplasm [14]. Our results clearly show that the
nuclear translocation and activation of STAT3 was sub-
stantially reduced by DIM treatment. Inhibition of
nuclear translocation in turn inhibits DNA binding
activity and transcriptional activity of STAT3 [37,38].
Specific DNA binding of STAT3 leads to transcriptional
activation of several downstream molecules such as sur-
vivin and Mcl-1. These results demonstrate that DIM
treatment blocks the transcriptional and DNA binding
activity of STAT3 and downregulates the expression of
survivin and Mcl-1. Our observations confirm previous
studies indicating that STAT3 inhibition downregulates
survivin or Mcl-1 in various cancers [27,39,40]. It is
noteworthy that a gene expression profiling of a pre-
vious study showed that survivin is a target of DIM [41].
Survivin overexpression is implicated in resistance to
cisplatin-induced apoptosis [42,43]. Our results showed
that survivin expression was substantially upregulated by
cisplatin treatment in ovarian cancer cells. However,
DIM treatment completely abolished the overexpression
of survivin by cisplatin, suggesting a potential role of
DIM in reducing cisplatin-mediated resistance.
Various cytokines and growth factors can activate
STAT3. IL-6 is well known to activate STAT3 by phos-
phorylation at Tyr-705. DIM not only eliminated constitu-
tive activation of STAT3, but also blocked IL-6 mediated
activation of STAT3. In addition, to convincingly establish
STAT3 as a target of DIM, cells were transfected with
STAT3 expression plasmid to activate STAT3 in ovarian
cancer cells. Induction of apoptosis by DIM was almost
completely blocked in cells overexpressing IL-6 or STAT3,
demonstrating that induction of apoptosis in our model
was mediated through STAT3 downregulation. Our data
indicating that DIM induces apoptosis by inhibiting
STAT3 was also supported by our STAT3 knockout stu-
dies, which demonstrated the induction of apoptosis when
STAT3 was knocked out by shRNA. These results agree
with a previous study showing the role of STAT3 in sup-
pressing apoptosis in pancreatic cancer cells [27]. Further-
more, DIM treatment dramatically reduced the secretion
of IL-6 not only in ovarian cancer cells but also in tumors.
Interestingly, a recent study reported higher IL-6 levels in
ovarian cancer patients [31]. This study indicated the IL-
6-STAT3-HIF axis as an important target for therapy in
ovarian cancer [31]. Our results show that DIM treatment
alone or in combination with cisplatin inhibited neovascu-
larization induced by IL-6, suggesting the antiangiogenic
potential of DIM. HIF-1a and VEGF play an important
role in angiogenesis. HIF-1a is short lived and degrades
proteasomally; however, MG132 blocks the degradation of
HIF-1a. Our results show that HIF-1a expression retained
by MG132 was suppressed as early as 6 h after DIM treat-
ment. IL-6 also activated HIF-1a, which clearly indicates
that HIF-1a perhaps is regulated through STAT3 in ovar-
ian cancer cells. It is obvious that inhibition of HIF-1a by
DIM was mediated through STAT3 in our model [13,44].
VEGF is another important regulator of angiogenesis and
its expression in cancer cells has been shown to correlate
with activation of STAT3 [33]. Previous reports have sug-
gested that overexpression of STAT3 increases VEGF
expression, leading to angiogenesis [33]. Hence disrupting
the activation of STAT3 would inhibit VEGF, blocking
angiogenesis [45]. Our results demonstrated that DIM
inhibits both VEGF expression and VEGF secretion. This
explains the mechanism of the antiangiogenic effects of
DIM in ovarian cancer cells in our study.
Cisplatin is a frontline drug used in the treatment of
advanced ovarian cancer [46]. Nonetheless, only 15% of
patients treated with cisplatin achieve long-term survi-
val; the rest experience persistent or recurrent disease
[47]. Moreover, cisplatin is associated with cytotoxicity
and resistance to chemotherapy [48,49]. STAT3 activa-
tion or overexpression is associated with cisplatin resis-
tance [5]. Our results demonstrate that DIM potentiates
the effect of cisplatin at one-quarter of its IC50 concen-
tration by inhibiting the activation of STAT3. Combina-
tion treatment blocked phosphorylation of STAT3 at
both Tyr-705 and Ser-727 when compared to cisplatin
treatment alone. Likewise, VEGF secretion and angio-
genic sprouting were noticeably reduced in combination
treatment as compared to cisplatin alone. These results
agree with previous studies that demonstrated inhibition
of STAT3 by an analog of aspirin potentiated the effects
of cisplatin [50]. The CI provides qualitative information
about the nature of drug interaction. CI values less than
1, equal to 1 or greater than 1 indicate synergistic, addi-
tive or antagonistic effects, respectively. Our CI values
for the combination treatment at both the concentra-
tions of DIM with cisplatin were less than 1, showing
the synergistic effects of DIM with cisplatin.
Oral administration of 3 mg DIM per day substantially
suppressed the growth of established ovarian tumors,
indicating the tumor regression potential of DIM. How-
ever, complete regression of tumors was not observed
with DIM. When given with cisplatin treatment, DIM
further retarded the growth of tumors. The tumors
from DIM or DIM plus cisplatin-treated mice clearly
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increased apoptosis. Similar to our in vitro observations,
cisplatin treatment caused a drastic increase in the
expression of survivin in the tumors, which was comple-
tely suppressed by DIM in combination treatment.
Interestingly, mice that received DIM did not show any
significant change in body weight when compared with
the weight of control mice. However, the mice that
received cisplatin and DIM showed a decrease in weight,
though this was not as drastic as in the mice that
received only cisplatin, suggesting that DIM may reduce
the systemic toxicity associated with cisplatin. DIM is a
major indole compound present in cruciferous vegeta-
bles, and is consumed on a daily basis [51]. A recent
single dose phase I clinical trial suggested that 200 mg
DIM is well tolerated not only by healthy volunteers but
also in patients with cervical cancer [21,52]. In the same
study 200 mg single dose produced a mean Cmax of 104
ng/ml and mean area under curve (AUC) of 553 h ng/
ml. The half-life of this dose was 2.6 ± 0.7 h. Interest-
ingly a single dose of DIM alone caused a significant
clinical improvement in patients with stage II and stage
III cervical intraepithelial neoplasia (CIN) [21]. Adminis-
tration of 2 mg/kg/day DIM via an oral route showed
improvement in pap smear results, human papilloma-
virus (HPV) status, and improved CIN by 1 to 2 grades
[21]. Several pharmacokinetic studies on DIM have sta-
t e dt h a tu pt o3 0 0m gi nas i n g l ed o s eo fD I Mc a nb e
tolerated by humans [52], indicating that our dose of
DIM falls within the accepted and tolerated dose. Cis-
platin in our studies was given intraperitoneally at a
dose of 5 mg/kg twice a week, which is 14 mg/m
2 when
converted to the equivalent human dose [53]. The
weekly dose of cisplatin ranges from 40 to 140 mg/m
2
in humans. We administered cisplatin twice a week,
with an additive effect of 28 mg/m
2,w h i c hi sm u c h
lower than the regular dosage typically given to patients
with cancer. If a low dose of cisplatin can be given to
patients without the loss of any therapeutic effect but
with reduced side effects, it would represent a significant
breakthrough in clinical practice. Nevertheless, further
clinical studies are needed to show that DIM can reduce
the side effects of cisplatin.
In conclusion, our results firmly establish that DIM
induces apoptosis in ovarian cancer cells by inhibiting
STAT3 signaling. Our results also provide evidence that
DIM inhibits the invasion of ovarian cancer cells and
angiogenesis by inhibiting HIF-1a and VEGF, which are
regulated by STAT3. Importantly, DIM potentiated the
effect of cisplatin both in culture and in vivo by inhibit-
ing STAT3. Taken together, the findings from our study
provide support for the use of DIM alone or in combi-
nation with cisplatin in preclinical and clinical settings
in the management of ovarian cancer patients.
Conclusions
For the first time, our study demonstrates that DIM tar-
gets STAT3 to suppress the growth of ovarian tumor
cells in vitro and in vivo.I m p o r t a n t l y ,D I Mi n h i b i t s
angiogenesis and invasion of ovarian cancer cells. Our
results also show that targeting STAT3 potentiates the
effect of cisplatin both in culture as well as in a tumor
xenograft model.
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